Angiotensin  II  Type  1  Receptor  Blockers  Increase  Tolerance  of  Cells  to  Copper  and  Cisplatin by Spincemaille, Pieter et al.
  
 
 
OPEN ACCESS | www.microbialcell.com 352 Microbial Cell | November 2014 | Vol. 1 No. 11 
www.microbialcell.com 
Research Article 
ABSTRACT  The human pathology Wilson disease (WD) is characterized by 
toxic copper (Cu) accumulation in brain and liver, resulting in, among other 
indications, mitochondrial dysfunction and apoptosis of hepatocytes. In an 
effort to identify novel compounds that can alleviate Cu-induced toxicity, we 
screened the Pharmakon 1600 repositioning library using a Cu-toxicity yeast 
screen. We identified 2 members of the drug class of Angiotensin II Type 1 
receptor blockers (ARBs) that could increase yeast tolerance to Cu, namely 
Candesartan and Losartan. Subsequently, we show that specific ARBs can in-
crease yeast tolerance to Cu and/or the chemotherapeutic agent cisplatin 
(Cp). The latter also induces mitochondrial dysfunction and apoptosis in 
mammalian cells. We further demonstrate that specific ARBs can prevent the 
prevalence of Cu-induced apoptotic markers in yeast, with Candesartan Cilex-
etil being the ARB which demonstrated most pronounced reduction of apop-
tosis-related markers. Next, we tested the sensitivity of a selection of yeast 
knockout mutants affected in detoxification of reactive oxygen species (ROS) 
and Cu for Candesartan Cilexetil rescue in presence of Cu. These data indicate 
that Candesartan Cilexetil increases yeast tolerance to Cu irrespectively of 
major ROS-detoxifying proteins. Finally, we show that specific ARBs can in-
crease mammalian cell tolerance to Cu, as well as decrease the prevalence of 
Cu-induced apoptotic markers. All the above point to the potential of ARBs in 
preventing Cu-induced toxicity in yeast and mammalian cells.  
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INTRODUCTION 
The human pathology Wilson disease (WD) is characterized 
by excess copper (Cu) accumulation in the brain and liver, 
leading to liver failure or cirrhosis and neurodegeneration 
[1-3]. Cu toxicity is directly related to mitochondrial dys-
function and apoptosis in mammalian cells [4] as it induces 
oxidative stress [5, 6] and crosslinking of mitochondrial 
membrane proteins causing the membrane to contract [7]. 
In addition, Cu causes a malfunction of complex IV of the 
respiratory chain [8] and increases acid sphingomyelinase 
(aSMase) activity [9], the latter leading to an increased 
production of the apoptosis inducer ceramide [10]. Fur-
thermore, the chemotherapeutic agent cisplatin (Cp) also 
induces mitochondrial dysfunction in mammalian cells by 
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TABLE 1. Effect of the selected ARBs on Cu and Cp-induced toxicity 
in yeast. ‘+’ and ‘-‘ denotes effective and ineffective, respectively. 
 Toxicity 
ARB Cu Cp 
Candesartan - + 
Candesartan Cilexetil + + 
Eprosartan - - 
Irbesartan - + 
Losartan + + 
Olmesartan - - 
Olmesartan Medoxomil + + 
Telmisartan - - 
Trityl Candesartan Cilexetil - - 
Valsartan + - 
 
decreasing respiration [11], causing mitochondrial mem-
brane depolarization [12], inducing the production of reac-
tive oxygen species (ROS) [13], and affecting mitochondrial 
structure and function [14]. In addition, mitochondria gen-
erate ROS upon exposure to Cp in both yeast and mamma-
lians cells [13], indicating that Cp-induced toxicity shows 
similarity between yeast and mammalian cells. In yeast, 
there are several contradictory reports on Cu-induced tox-
icity and mitochondrial dysfunction. Some reports have 
demonstrated the negative impact of non-lethal Cu doses 
on the mitochondrial proteome and function in yeast, re-
sulting in decreased ATP production and activation of the 
oxidative stress response [15], and mitochondrial abnor-
malities [16]. In contrast, Cu-treatment of yeast has also 
been reported to increase the mitochondrial Cu content 
without causing respiratory deficits [17]. Apart from direct 
effects of Cu on mitochondrial function, Cu toxicity in S. 
cerevisiae has been linked to perturbations in sphingolipid 
(SL) homeostasis [18], which are crucial membrane com-
ponents with regard to apoptosis [19] and mitochondrial 
function [20, 21]. In contrast, Lee and coworkers did not 
show any alterations in a subset of SL species in response 
to Cu treatment [22]. Hence, the question whether Cu in-
deed results in mitochondrial dysfunction in yeast remains 
under debate. Nonetheless, by using a Cu-induced toxicity 
screen in yeast, we previously identified an Arabidopsis 
thaliana-derived decapeptide termed OSIP108 [23] as a 
peptide that can increase yeast tolerance to Cu. More spe-
cifically, we showed that OSIP108 prevents Cu-induced 
apoptosis in yeast and human cells, and preserves mito-
chondrial ultrastructure in human cells [18]. Furthermore, 
we were able to link these observations to perturbations in 
SL homeostasis by OSIP108 [18]. In addition, we translated 
these data toward a novel zebrafish model for Cu toxicity 
and showed that OSIP108 injections into zebrafish larvae 
prevented Cu-induced hepatotoxicity and decreased oxida-
tive stress levels [24]. Thus, despite the contradictory re-
ports in literature, by using our Cu-toxicity yeast screen, we 
identified OSIP108, and were able to translate our yeast 
data to higher eukaryotic cell models, as well as to an in 
vivo model for Cu-intoxication, thereby validating our Cu-
toxicity screen in yeast in the context of apoptosis and 
mitochondrial dysfunction. 
In an effort to identify small molecules that can allevi-
ate Cu-induced toxicity in yeast, we screened the Pharma-
kon 1600 repositioning library consisting of 1600 drugs, 
which are marketed or have been tested in clinical trials. 
Drug repositioning is referred to as the identification and 
development of new uses of existing or abandoned drugs. 
It possesses several advantages over de novo drug discov-
ery such as known safety and pharmacokinetic profiles, as 
well as knowledge of manufacturing and toxicology of the 
compounds investigated [25, 26]. Current fields of interest 
for application of such repurposing strategy include the 
identification of novel antibiotics [27], the increase of ef-
fectiveness of existing antimycotics by potentiation [28], 
but also novel treatments for orphan diseases [29]. The 
Pharmakon library was screened in our Cu-based yeast-
toxicity screen [18]. Repurposed compounds that scored 
positive in this Cu-based yeast toxicity screen were further 
tested for their potential to increase yeast tolerance to Cp, 
another inducer of mitochondrial dysfunction. Subsequent-
ly, we translated these data to a mammalian cell setting. 
All our data point to the protective effect of ARBs against 
Cu-induced toxicity. 
 
RESULTS  
Screening for compounds that can increase yeast toler-
ance to Cu 
The Pharmakon 1600 repositioning library was screened 
for agents that can increase yeast tolerance to Cu as de-
scribed previously [18]. Briefly, WT yeast was inoculated in 
solid growth medium containing a lethal Cu concentration 
(100 µM) and the viability indicator dye MTT (0.1 mg/mL). 
All 1600 compounds (10 mM in DMSO) were spotted (5 µL) 
onto the solid agar. Following 24 h of incubation, the plates 
were checked for development of purple halos around the 
spotted compounds, resulting from the conversion of the 
viability dye MTT and thus indicative for viable cells. Given 
that Cu chelation or sequestration is one of the main cellu-
lar Cu detoxification mechanisms [30, 31], we identified 
several agents with known chelating activity such as 
Deferoxamine Mesylate [32] and Oxyquinoline Sulfate [33]. 
Hence, such agents were omitted to exclude aspecific Cu 
chelation. This resulted in the identification of seven com-
pounds (data not shown) that are not known to chelate Cu 
and can increase tolerance of yeast cells to Cu. Among 
them were two members of the drug class of Angiotensin II 
Type 1 receptor blockers (ARBs) [34], namely Candesartan 
and Losartan. 
Given the fact that several studies have documented 
beneficial effects of ARBs, such as Candesartan and Losar-
tan, on human pathologies linked to mitochondrial dys-
function and apoptosis, such as diabetes, Alzheimer dis-
ease and aging [35-42], we selected the drug class of ARBs 
for further characterization of their activity using the mod-
el yeast S. cerevisiae. 
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Angiotensin II Type 1 receptor blockers increase yeast 
survival in presence of toxic Cu and Cp 
We investigated the effect of a selection of commercially 
available ARBs, namely Eprosartan, Irbesartan, Losartan, 
Olmesartan, Olmesartan Medoxomil, Telmisartan, Trityl 
Candesartan Cilexetil and Valsartan (Table 1), on yeast 
survival in presence of toxic Cu and Cp. The prototype of 
the class of ARBs is Losartan [43], from which additional 
ARBs were derived based on modification of its chemical 
structure, such as Candesartan, Valsartan and Olmesartan 
[34]. We found that incubation of yeast cells with 2 mM Cu 
resulted in approx. 23% yeast survival, whereas treatment 
of Cu-stressed yeast with either 100 µM Candesartan 
Cilexetil, Losartan, Olmesartan Medoxomil or Valsartan 
significantly increased yeast survival. No significant in-
crease in survival of Cu-stressed yeast cells was observed 
upon incubation with 100 µM Candesartan, Eprosartan, 
Irbesartan, Olmesartan, Telmisartan or Trityl Candesartan 
(Fig. 1 a). These results indicate that particular ARBs can 
increase yeast tolerance to excess Cu. Note that while 
Candesartan was identified during our screen, it failed to 
significantly increase yeast survival in presence of Cu, as 
determined by plating colony-forming units (CFU). It is ex-
pected that the CFU-based assay is more stringent, result-
ing in the selection of the most potent ARBs with regard to 
increasing Cu tolerance.  
We further evaluated the effect of the ARBs against Cp-
induced toxicity in yeast. Incubation of yeast cells with 250 
µM Cp decreased yeast survival to about 5% whereas co-
treatment with either 100 µM Candesartan, Candesartan 
Cilexetil, Irbesartan, Losartan or Olmesartan Medoxomil 
significantly increased survival as compared to control 
treatment. No significant effect on survival of Cp-stressed 
yeast cells was observed with treatment of 100 µM Epro-
sartan, Olmesartan, Telmisartan, Trityl Candesartan Cilexe-
til or Valsartan (Fig. 1 b). These data indicate that particular 
ARBs can prevent Cp-induced toxicity in yeast.  
Interestingly, in our experiments only Candesartan 
Cilexetil, Losartan and Olmesartan Medoxomil increased 
yeast tolerance to both Cu and Cp (Table 1), suggesting 
that these three ARBs are the most interesting candidates. 
Structural classification of ARBs is based on the cycle re-
placing the imidazole ring in Losartan: in Candesartan 
Cilexetil, this imidazole group is replaced by a benzimidaz-
ole group, while in Olmesartan Cilexetil it is a imidazole 
derivate [34]. Since these three ARBs significantly in-
creased yeast tolerance to both Cu and Cp (Fig. 1 a, b) and 
Candesartan Cilexetil is the most structurally different from 
Losartan (Fig. 1 c), we selected the prototype ARB Losartan 
and Candesartan Cilexetil for further characterization. For a 
more detailed description on the chemical structure of 
ARBs the reader is referred to [34, 44].  
In order to gain insight into the efficacy of Candesartan 
Cilexetil and Losartan against Cu or Cp-induced toxicity in S. 
cerevisiae, we evaluated different doses (25 µM – 100 µM) 
of either ARB on yeast survival in presence of toxic Cu (2 
mM) or Cp (250 µM). We found that all tested doses of 
Candesartan Cilexetil and Losartan significantly increased 
yeast tolerance to Cu (Fig. 1 d). Conversely, we observed 
that only 100 µM Candesartan Cilexetil and 100 µM Losar-
tan significantly increased yeast survival in presence of Cp 
(Fig. 1 e). These data indicate that ARBs can protect yeast 
against Cu-induced toxicity in a broad concentration range, 
while only high doses of ARBs confer protection against Cp-
induced toxicity.  
In order to exclude a general stress-protectant effect of 
ARBs, we also evaluated the effect of ARBs against a panel 
of noxious insults such as tunicamycin, the anti-convulsant 
valproic acid, acetic acid and CCCP. To this end we moni-
tored yeast growth in presence of either insult in absence 
(control) or presence of 100 µM Candesartan Cilexetil 
and/or Losartan. In contrast to the effect of ARBs on yeast 
growth in presence of Cp, we did not observe an effect of 
the tested ARBs against either insult (Supplemental Fig 1 a-
e). These results suggest that ARBs cannot rescue general 
yeast growth defects induced by toxic triggers including 
tunicamycin, valproic acid, acetic acid or CCCP and hence, 
that the ARB-protecting action against noxious insults 
seems toxin-specific. 
 
ARBs affect Cu-induced apoptotic markers in yeast  
As excess Cu is known to induce apoptosis [18, 45], we 
investigated the effect of Losartan and Candesartan Cilexe-
til on Cu-induced ROS production and DNA fragmentation, 
both markers of apoptosis [46]. In line with our previous 
results [18], we observed that 2 mM Cu significantly in-
creased the amount of cells stained positive with dihy-
droethidium (DHE) (Fig. 2 a), indicating the induction of 
ROS and more specifically superoxide by Cu. Co-incubation 
with 100 µM Candesartan Cilexetil significantly decreased 
the levels of DHE positive cells in presence of 2 mM Cu (Fig. 
2 a). By using the Terminal dUTP Nick End Labeling (TUNEL) 
assay, we observed that 2 mM Cu significantly induced 
DNA fragmentation in yeast, while treatment with either 
100 µM Candesartan Cilexetil or Losartan significantly de-
creased the amount of Cu-induced TUNEL positive cells (Fig 
2 b). These data suggest that specific ARBs may differen-
tially affect Cu-induced markers of apoptosis, and that 
Candesartan Cilexetil is the most potent in decreasing 
these markers. 
In order to increase our understanding of Cu-induced 
cell death in yeast, which occurs presumably via apoptosis 
[18, 45], we evaluated the Cu-tolerance and the rescuing 
effect of ARBs of wild type yeast (BY4741) and a selection 
of yeast mutants defective in components of the apoptotic 
machinery such as Δaif1, Δnuc1 or Δyca1 mutants. To this 
end, we spotted serial dilutions of these yeast cultures 
onto Cu-containing (1.25 mM – 1.5 mM) solid growth me-
dia in the presence of control (0.5% DMSO) or Candesartan 
Cilexetil (100 µM). This selection of mutants was also re-
cently tested to characterize cell death induced by Mentha 
piperita essential oil in S. cerevisiae [47]. Aif1p and Nuc1p 
are mitochondrial cell death effectors that translocate to 
the nucleus in response to apoptotic stimuli such as  hydro- 
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FIGURE 1: ARBs prevent Cu and Cp-induced killing of yeast cells. Yeast cells were incubated with 2 mM Cu for 4 h (a, d) or 250 µM Cp for 
16 h (b, e) in presence of vehicle control (V.c, 2.5% DMSO) or 100 µM Candesartan (1), Candesartan Cilexetil (2), Eprosartan (3), Irbesartan 
(4), Losartan (5), Olmesartan (6), Olmesartan Medoxomil (7), Telmisartan (8), Trityl Candesartan Cilexetil (9) or Valsartan (10). (c) Chemical 
structure of the prototype Losartan, of which Candesartan Cilexetil and Olmesartan Medoxomil are derived. The benzimidazole group in 
Candesartan Cilexetil and the imidazole ring in Losartan and Olmesartan Medoxomil are circled. Taken and adapted from [44]. Yeast sur-
vival in presence of different doses of Candesartan Cilexetil or Losartan upon treatment with 2 mM Cu (d) or 250 µM Cp (e). Survival was 
calculated by determining CFU/ml as compared to untreated control cells (no Cu or Cp). Experiment performed in quadruplicate, with at 
least two biological repeats. (*P < 0.05; **P < 0.01; ***P < 0.001; ANOVA test using Tukey correction). 
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gen peroxide [48, 49]. Yca1p is the yeast metacaspase and 
is implicated as a crucial cell death effector during H2O2- or 
acetic acid-induced apoptosis [50, 51]. We observed that 
the Δyca1 mutant did not display altered susceptibility to 
toxic Cu as compared to wild type yeast, which is in line 
with literature [18, 45, 52], nor did Δaif1 or Δnuc1 mutants 
(Supplemental Fig. 2, middle and right panel). Candesartan 
Cilexetil supplementation, however, increased viability of 
all yeast mutants (Supplemental Fig. 2, middle and right 
panels). Taken together, these data suggest that Cu-
induced apoptosis in yeast is independent of Aif1p, Nuc1p 
and Yca1p, and that Candesartan Cilexetil increases yeast 
tolerance to Cu independently of the latter three proteins. 
 
Exogenous addition of the plant decapeptide OSIP108 
does not affect the protective effect of Candesartan 
Cilexetil against Cu-induced toxicity in yeast 
As we previously identified the A. thaliana-derived 
decapeptide OSIP108 [23] as a potent rescuer from Cu 
toxicity of yeast and human cells [18], we evaluated 
whether OSIP108 can influence the effect of Candesartan 
Cilexetil on Cu-induced cell death in yeast. Thus, we inves-
tigated a putative synergy between Candesartan Cilexetil 
and OSIP108.  
To this end, we first identified an OSIP108 dose that did 
not affect yeast Cu-tolerance, being 12.5 µM or 25 µM 
OSIP108 (Fig. 2 c). Subsequently, we found that these 
OSIP108 doses neither increased nor decreased the protec-
tive effect of Candesartan Cilexetil (100 µM) against Cu-
induced toxicity in yeast (Fig. 2 c), suggesting that the 
structurally unrelated OSIP108 and Candesartan Cilexetil 
affect yeast tolerance to Cu via distinct pathways. 
 
Candesartan Cilexetil increases yeast mutant tolerance to 
Cu 
To get preliminary insights into the role of ROS during Cu-
induced toxicity in yeast, we evaluated the Cu tolerance of 
a panel of yeast deletion mutants defective in ROS detoxi-
fication (Δcta1, Δctt1, Δgrx5, Δsod1, Δsod2), at least partly 
defective in cytoplasmic ROS production (Δyno1) or Cu 
sequestration (Δcrs5, Δcup2). The catalases Cta1p and 
Ctt1p detoxify the ROS H2O2 in the peroxisomes and cytosol, 
respectively [53, 54]. During respiratory growth conditions 
Cta1p also resides in the mitochondria [54]. In addition, the 
superoxide dismutases Sod1p and Sod2p detoxify superox-
ide, thereby generating oxygen and H2O2, mainly in the 
cytosol and mitochondria, respectively [55, 56]. Further-
more, we included yeast mutants defective in Grx5p, a 
mitochondrial glutathione-dependent oxidoreductase that 
plays a crucial role in defense against oxidative stress [57], 
and Yno1p, a NADPH oxidase in the endoplasmic reticulum 
that is responsible for extra-mitochondrial superoxide pro-
duction [58]. In addition, given that Cu sequestration is one 
of the major Cu-detoxification mechanisms, we included 
the Cu-binding metallothionein Crs5p [59] and the Cu-
binding transcription factor Cup2p, which initiates tran-
scription of the genes encoding the metallothioneins CUP1-
1 and CUP1-2 [60, 61]. Serial dilutions of wild type 
(BY4741) and these mutants were spotted onto control (0 
 
FIGURE: 2. ARBs reduce levels of Cu induced apoptotic markers 
in yeast. Yeast cells were incubated with 2 mM Cu for 4 h with 
control treatment (black bars), Losartan (white bars) or Candesar-
tan Cilexetil (gray bars). Following treatment, cells were stained 
with DHE (a) or TUNEL assay (b) and subsequently analyzed by 
flow cytometry or counted manually after fluorescence microsco-
py, respectively. Three biological repeats were used. (*P < 0.05; 
**P < 0.01; ***P < 0.001; ANOVA test using Tukey correction). (c) 
OSIP108 does not affect the rescue effect of Candesartan Cilexe-
til. Yeast cells were incubated with 2 mM Cu for 4 h with control 
treatment, Candesartan Cilexetil (100 µM) in absence (2% DMSO) 
or presence of OSIP108 (12.5 µM – 25 µM). Following incubation, 
cells were plated on YPD agar plates and survival was calculated 
as compared to CFU/ml of cells receiving no Cu. Experiments per-
formed in quadruplicate with three biological repeats. (*P < 0.05; 
**P < 0.01; ***P < 0.001; ANOVA test using Tukey correction). 
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mM Cu) or Cu-containing (1.25 mM – 1.5 mM) solid growth 
media supplemented with either control (0.5% DMSO) or 
Candesartan Cilexetil (100 µM). 
We found that while loss of Sod1p, Cup2p or Crs5p se-
verely increased yeast sensitivity to Cu, loss of Sod2p or 
Yno1p moderately increased yeast tolerance to Cu (Fig. 3, 
middle and right panels). Loss of Sod2p was already previ-
ously shown to increase yeast tolerance to copper nitrate 
[62] while loss of Yno1p is documented to increase yeast 
tolerance to apoptotic stimuli [58]. In contrast, supplemen-
tation with Candesartan Cilexetil increased the Cu toler-
ance of all yeast mutants, except Δcrs5 and Δcup2 mutants. 
Given the evident increased susceptibility to Cu of the lat-
ter two mutants, this suggests that both proteins are cru-
cial in conferring Cu tolerance in yeast and their loss is det-
rimental for yeast viability in presence of Cu to an extent 
 
FIGURE 3: Effect of Candesartan Cilexetil on Cu tolerance of yeast mutants. Serial dilutions of wild type (WT), Δcta1, Δctt1, Δgrx5, Δsod1, 
Δsod2, Δyno1, Δcup2 and Δcrs5 were spotted onto control (0 mM Cu) or Cu-containing (1.25 mM – 1.5 mM) solid SC media in presence of 
control (0.5% DMSO; top panels) or 100 µM Candesartan Cilexetil (bottom panels). Growth was evaluated following 48 h incubation at 30°C. 
Data representative for two biological repeats. 
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that Candesartan Cilexetil is unable to counteract this tox-
icity. However, additional experiments are required to de-
termine whether Candesartan Cilexetil directly acts on 
metallothionein levels/activity. Surprisingly, given the in-
creased and decreased susceptibility of Δsod1 and Δyno1 
mutants to Cu, respectively, this points to deleterious cy-
toplasmic, rather than mitochondrial, ROS production dur-
ing Cu-induced toxicity in yeast. However, this does not 
exclude mitochondrial ROS production upon Cu treatment 
in yeast. Note that Cu is an essential cofactor for Sod1p, 
and loss of this protein may trigger defective Cu storage. 
Taken together, further research is needed to pinpoint the 
cellular targets of Candesartan Cilexetil in the context of Cu 
toxicity in yeast. 
 
ARBs prevent Cu-induced apoptosis in the human hepa-
toma HepG2 cell line  
In an effort to translate our yeast data to a higher eukary-
otic cell model, we investigated the effect of the ARBs 
Candesartan Cilexetil and Losartan on Cu-induced apopto-
sis in the human hepatoma HepG2 cell line. To this end we 
first evaluated HepG2 survival in absence of Cu upon incu-
bation with Candesartan Cilexetil and Losartan. In initial 
experiments we titrated the Candesartan Cilexetil or Losar-
tan dose to investigate a putative ARB-associated toxicity 
towards HepG2 cells, and observed that while doses higher 
than 25 µM Candesartan Cilexetil induced killing of HepG2 
cells, 100 µM Losartan did not have an effect on cell viabil-
ity (data not shown). Subsequently, we investigated the 
effect of 25 µM Candesartan Cilexetil and 100 µM Losartan 
on HepG2 cell viability in presence of different Cu concen-
trations. While ARB treatment in presence of Cu doses that 
decreased cell viability by less than 50% did not result in 
any significant effects (Fig. 4 a), we found that only 100 µM 
Losartan significantly increased cell viability upon treat-
ment with 1 mM or 1.25 mM Cu (Fig. 4 a): HepG2 viability 
decreased to approx. 28% or 8% upon treatment with 1 
mM or 1.25 mM Cu, respectively, while coincubation with 
100 µM Losartan resulted in 46% or 26% viability respec-
tively. Coincubation with 25 µM Candesartan Cilexetil and 
Cu did not affect cell viability. These data suggest that par-
ticular ARBs confer protection against severe Cu-induced 
cell death in mammalian cells. 
Subsequently, similar as to our yeast experiments, we 
evaluated the effect of Candesartan Cilexetil and Losartan 
on Cu-induced apoptosis in HepG2 cells by FLUOS-labeled 
Annexin V staining. In line with literature [9, 18], we ob-
served an increased prevalence of Annexin V-positive cells 
upon treatment with 1.5 mM Cu, indicating Cu-induced 
apoptosis (Fig. 4 b). In addition, while treatment with 100 
µM Losartan decreased Cu-induced apoptosis (Fig. 4 b), 25 
µM Candesartan Cilexetil did not (data not shown). Taken 
together, these data indicate that specific ARBs can pre-
vent Cu-induced cell death and apoptosis in human cells. 
 
DISCUSSION 
In the present study we report on the screening of the 
Pharmakon 1600 repositioning library in order to identify 
agents that increase tolerance to Cu-induced toxicity in 
yeast and the identification of the drug class of ARBs. Next, 
we showed that specific ARBs increase yeast tolerance to 
Cu and Cp, and affect markers of Cu-induced apoptosis. 
Likewise, we found that specific ARBs increase human cell 
line tolerance to Cu and decrease the prevalence of apop-
totic markers.  
Our Cu-based yeast toxicity screen resulted in the iden-
tification of 7 clinically used drugs that can significantly 
increase yeast tolerance to Cu (data not shown) including 
the ARBs Candesartan and Losartan that are used as anti-
hypertensive drugs [63]. The drug class of ARBs is of par-
ticular interest given the numerous reports that describe 
beneficial effects of ARBs in human pathologies related to 
mitochondrial dysfunction. For instance Losartan treat-
ment reduces mitochondrial dysfunction in aged and spon-
FIGURE 4: Losartan 
prevents Cu-induced 
apoptosis in HepG2 
cells. (a) Losartan in-
creases HepG2 cell 
viability in presence of 
Cu. HepG2 cells were 
treated with Cu (0.75 
mM - 1.25 mM) in 
presence of control (1% 
DMSO, black bars), 25 
µM Candesartan Cilex-
etil (white bars) or 100 
µM Losartan (grey 
bars). Following 48 h of 
incubation, cell viability 
was determined by 
MTT viability staining, and expressed as compared to cells receiving no Cu. Biological repeat is four. (***P < 0.001; ANOVA test using Tukey 
correction). (b) Losartan prevents Cu-induced apoptosis in HepG2 cells. HepG2 cells were treated for 1.5 mM Cu in absence (control) or pres-
ence of 100 µM Losartan for 24 h. Subsequently, cells were stained with FLUOS-labeled Annexin V and samples were analyzed by flow cy-
tometry. Biological repeats is three. (**P < 0.01; Student t-test). 
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taneously hypertensive rats [35, 36]. Furthermore, in a 
comparative study, Losartan, Olmesartan and Valsartan 
were shown to prevent liver fibrosis in alloxan-induced 
diabetic rats. In contrast to Losartan and Valsartan treat-
ment, Olmesartan treatment preserves mitochondrial ul-
trastructure [39]. Even protective effects of ARBs against 
Alzheimer disease have been suggested [40, 41] and long 
term Losartan administration to rats significantly increases 
life span [42]. Recently, Olmesartan treatment was shown 
to attenuate high fat diet-induced decreased mitochondrial 
respiration [64], while Losartan was reported to ameliorate 
mitochondrial function in indirect flight muscles in Dro-
sophila melanogaster [65]. An additional advantage of 
ARBs is that they are well tolerated and not associated 
with class-related side effects [66, 67]. In all these studies, 
however, the underlying molecular mechanism of these 
beneficial effects of ARBs on mitochondrial function and 
tolerance to apoptosis were not addressed.  
While some ARBs are specific to either Cu or Cp-
induced toxicity (Valsartan or Candesartan and Irbesartan, 
respectively), other ARBs do not show any effect to either 
toxic insult. However, the ARBs Candesartan Cilexetil, 
Losartan and Olmesartan Medoxomil display activity 
against both Cu and Cp (Table 1). Interestingly, Candesar-
tan Cilexetil and Olmesartan Medoxomil are ester prodrug 
versions of their parent compound Candesartan and 
Olmesartan, respectively, and display improved bioavaila-
bility [68, 69]. It is therefore plausible that the uptake of 
these prodrugs in yeast is more efficient, and thereby is a 
determinant of their protective effect against Cu and Cp. 
Nonetheless, given the effect of these aforementioned 
ARBs against both toxic agents, this suggests that Cu and 
Cp toxicity in yeast may be mediated by overlapping path-
ways. Common defense mechanisms against Cu and Cp 
have been described in yeast and mammalian cells. For 
example, pre-treatment of yeast cells with Cu or Cp is re-
ported to increase yeast tolerance to Cp or Cu, respectively, 
in both cases due to degradation and delocalization of the 
Cu transporter Ctr1p [70]. Additionally, at low Cu concen-
trations that do not affect Ctr1p, Cu also protects against 
Cp-induced toxicity in yeast [71]. In mammalian cells, Cu 
and Cp increase activity of aSMase, leading to an increased 
production of the apoptosis inducer ceramide [9, 72, 73] 
and both Cu and Cp-induced toxicity have also been asso-
ciated with pro-apoptotic Bax [74-80]. As we observed that 
ARBs cannot rescue yeast growth defects induced by nox-
ious insults such as tunicamycin, valproic acid, acetic acid 
or CCCP, it seems that the protective effect of ARBs is tox-
in-specific. 
A Cu-chelating activity has never been reported for 
ARBs. However, Losartan has been described to spontane-
ously form an insoluble complex with Cu [81], and ARB-Cu 
complexes have been reported to display anti-oxidant ac-
tivity [82-84], pointing to the possibility of Cu-chelation by 
ARBs. Whether the underlying mechanistic event that gov-
erns the ARB-mediated protection against Cu-induced tox-
icity is attributed to Cu complexation by ARBs has yet to be 
investigated. As Cu-complexation does not explain the 
ARBs’ effect in Cp toxicity, it is conceivable that ARBs in-
crease yeast tolerance to Cu and Cp in other ways.  
With respect to Cp toxicity, there are some in vivo re-
ports that describe the effect of ARBs against Cp-induced 
toxicity. For instance, chronic Losartan treatment in rats 
after Cp administration improves weight gain following Cp-
induced reduced food intake and weight loss [85]. Losartan 
also reduces Cp-induced lipid peroxidation and glutathione 
depletion in rat kidneys [86]. In addition, combination 
therapies with Losartan and Vitamin E [87] or C [88] as 
treatment for Cp-induced nephrotoxicity in rats have been 
tested, but without any significant result. Noteworthy is 
that both Candesartan and a combination of Candesartan 
and Cp have been shown to suppress tumor growth in a 
xenograft model for bladder cancer in mice. However, the 
combination of Candesartan and Cp proved to be less ef-
fective than Candesartan alone, suggesting a protective 
effect of Candesartan against Cp-induced apoptosis [89].  
Yeast is a powerful model organism to study various 
cellular processes, including mitochondrial function and 
apoptosis due to conservation of their regulatory pathways 
[90-93]. Apart from antifungal drug discovery purposes [28, 
94], yeast-based screens are often used to identify com-
pounds that can affect disease-relevant targets, such as for 
instance calcineurin [95], human telomerase [96], or syn-
ergetic DNA-damaging drug combinations [97]. Also, yeast 
assays have been reportedly used to gain insight into the 
mode of action of clinically used compounds [98]. For in-
stance, the anti-anginal drug Molsidomine [99] was shown 
to target lanosterol synthase in the sterol biosynthetic 
pathway [98].  
The results of this study indicate that Cu-induced apop-
tosis in yeast is independent of Aif1p, Nuc1p or Yca1p. In 
addition, the data presented here also highlight the fact 
that despite the conservation of several important meta-
bolic pathways, there still remain yeast and mammalian 
cell-specific aspects: while in mammalian cells Cu-induced 
toxicity is directly related to impact on mitochondrial func-
tion [4-8], there are contradictory reports regarding Cu-
induced toxicity and mitochondrial function in yeast [15-
17]. Indeed, the loss of the cytoplasmic ROS generator 
Yno1p or cytoplasmic Sod1p increases or decreases yeast 
tolerance to Cu, respectively, indicating that Cu-induced 
toxicity in yeast seems associated with detrimental cyto-
plasmic, but does not exclude, mitochondrial ROS produc-
tion. Still, by using Cu-induced toxicity in yeast as a screen-
ing model, we were able to identify the plant-derived pep-
tide OSIP108 as an agent that prevents Cu-induced apopto-
sis in yeast and human cells, preserves mitochondrial ultra-
structure in human cells, but also prevents Cu-induced liver 
damage and decreases oxidative stress levels in zebrafish 
larvae [18, 23, 24]. Hence, these reports illustrate the valid-
ity of our screen to identify agents with a putative applica-
tion in persevering mitochondrial function and preventing 
apoptosis. This is of particular importance as mitochondrial 
dysfunction, ROS and apoptosis have been linked to several 
human conditions such as aging, cancer [100], diabetes 
[101, 102] and non-alcoholic steatohepatitis [103], but also 
neurodegenerative disorders [104] including Alzheimer 
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disease [105] and Parkinson’s disease [106, 107], and rare 
diseases such as WD [4]. Current treatment options for 
mitochondrial dysfunction-related disorders are inade-
quate and mostly consist of the administration of cofactors 
and oxygen radical scavengers [108-110]. Thus, there still is 
an urgent need for novel treatments in combating mito-
chondrial dysfunction-related disorders and ARBs may 
show promise, as well as OSIP108, in this regard.  
Noteworthy is that while the effects of ARBs on cellular 
metabolism in a higher eukaryotic setting is typically based 
on its ability to block the interaction between Angiotensin 
II and the Angiotensin II Receptor Type 1, neither the lig-
and nor the receptor have thus far been identified in S. 
cerevisiae, suggesting the existence of additional cellular 
targets for ARBs [44, 63]. Thus, it is plausible that ARBs 
mediate Cu-tolerance in yeast and mammalian cells irre-
spective of their known cellular targets. Hence, despite 
that our yeast data show promise regarding the protective 
effect of ARBs against Cu-induced toxicity, it therefore re-
mains to be investigated whether their mode of action in 
yeast can be translated to a mammalian setting. 
In conclusion, this study again highlights the potential 
of S. cerevisiae as a model organism, to identify novel 
compounds that increase tolerance to inducers of mito-
chondrial dysfunction in mammalian cells such as Cu. Un-
raveling the anti-Cu mode of action of ARBs in yeast might 
reveal new therapeutic targets in treatment of WD, or mi-
tochondrial dysfunction-related conditions in general.  
 
MATERIALS AND METHODS 
Materials and microorganisms 
The yeast strains used in this study is Saccharomyces cere-
visiae wild type yeast strain BY4741 (WT) and corresponding 
mutants (Δaif1, Δcrs5, Δcta1, Δctt1, Δcup2, Δgrx5, Δnuc1, 
Δsod1, Δsod2, Δyca1, Δyno1) (Euroscarf, Germany) were cul-
tured in SC (0.77 g/L complete amino acid supplement mixture 
(CSM) (Bio 101 Systems); 6.7 g/L yeast nitrogen base without 
amino acids (YNB); 20 g/L glucose). HepG2 cells, human hepa-
toma cells, were purchased from ATCC (Rockville, MD, USA) 
and grown in Minimal Essential Medium (MEM) supplemented 
with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml peni-
cillin and 100 µg/ml streptomycin. Cis-
diamminedichloroplatinum (II) (cisplatin, Cp), copper sulphate 
pentahydrate and copper chloride (CuCl2, Cu) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in 
DMSO and distilled H2O respectively. Note that there is some 
controversy in literature regarding the use of DMSO as solvent 
for Cp. We however did not observe major differences in Cp-
induced toxicity in yeast upon using either DMSO or 0.9% NaCl 
in distilled H2O as solvent for Cp. The Pharmakon 1600 reposi-
tioning library (10 mM in DMSO) was obtained from Mi-
croSource Discovery Systems, Gaylordsville, CT, USA. All Angi-
otensin II Type 1 receptor blockers (ARBs) (Candesartan, Can-
desartan Cilexetil, Eprosartan, Irbesartan, Losartan, Olmesar-
tan, Olmesartan Medoxomil, Telmisartan, Trityl Candesartan 
Cilexetil and Valsartan, as listed in Table 1) were purchased 
from Sequoia Research Products (Pangbourne, UK) and dis-
solved in DMSO. Protocols involving the effect of ARBs on 
yeast growth in presence of valproic acid, tunicamycin, acetic 
acid or CCCP are included in the supplementary data. 
Yeast Cu toxicity screen in solid media 
The Pharmakon 1600 repositioning library was screened using 
a Cu-induced toxicity yeast model as described [18]. 
 
Yeast survival in presence of Cu and Cp in liquid media 
A WT overnight culture (ONC) in SC was diluted to OD600 = 2 in 
fresh SC and incubated with 2% DMSO (vehicle control) or ARB 
(25 µM – 100 µM) in presence or absence of 2 mM CuSO4 or 
250 µM Cp for 4 h or 16 h, respectively. Following incubation 
at 30°C and 250 rpm, proper cell dilutions were plated onto 
YPD agar plates (1% Yeast extract, 2% Bacteriological peptone, 
2% glucose and 1.5% agar) and survival was calculated as 
compared to an unstressed yeast culture. Regarding the effect 
of dhSph or OSIP108 on yeast tolerance to Cu upon treatment 
with Candesartan Cilexetil, cells were treated as described 
above in absence (2% DMSO) or presence of OSIP108 (12.5 
µM or 25 µM) and 100 µM Candesartan Cilexetil.  
 
Detection of apoptotic markers in yeast 
To determine Cu-induced ROS production Cu-treated yeast 
cells were stained with 5 µg/ml dihydroethidium (Molecular 
Probes) (DHE) and analyzed by flow cytometry as described 
[18]. Subsequent data analysis was performed by using FlowJo 
software (Tree Star Inc., Ashland, MA, USA). For detection of 
DNA fragmentation, yeast cells were stained by Terminal de-
oxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay as described [18]. TUNEL positive cells were imaged by 
fluorescence microscopy (Zeiss Axio Imager Z1 fluorescence 
microscope) and at least 600 cells/samples were manually 
counted. 
 
Yeast spot plating 
Overnight yeast cultures in SC were diluted to OD600 = 0.01 
and 5 fold-serial dilutions were spotted on control plates (0 
mM CuSO4) or Cu-containing (1.25 mM – 1.5 mM) solid SC 
medium (1.5% agar) in presence of 0.5% DMSO (control) or 
100 µM Candesartan Cilexetil. Subsequently, plates were in-
cubated at 30°C for 48 h. 
 
HepG2 Cu toxicity experiments  
HepG2 viability upon treatment with CuCl2 (0.75 mM – 1.25 
mM) in presence of 1% DMSO (control), 25 µM Candesartan 
Cilexetil or 100 µM Losartan was performed as described pre-
viously [21]. Briefly, 104 cells were seeded in triplicates in 96 
well plates and incubated for 24 h. Next day, cells were treat-
ed with copper and/or Candesartan Cilexetil or Losartan and 
further incubated for 48 h. Cell viability was determined by 
MTT assay and results were calculated as percentage of un-
treated control cells.  
 
Detection of apoptosis and oxidative stress in HepG2 cells 
Detection of apoptotic markers by FLUOS-Annexin V (Roche 
Diagnostics NV Belgium, Belgium) staining and subsequent 
flow cytometry analysis in HepG2 cells upon treatment with 
1.5 mM CuCl2 in presence of 1% DMSO (control) or 100 µM 
Losartan was performed as described previously [21]. Briefly, 
106 cells were seeded in a 6 well plate and incubated for 24 h. 
Next day, cells were treated with copper and control or Losar-
tan Cilexetil and Losartan for an additional 24 h. Cell culture 
supernatants and cells were collected and subjected to FLUOS-
Annexin V staining followed by flow cytometry analysis 
(Beckman Coulter, Germany). 
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